Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Sponsor

Dana-Farber Cancer Institute (Other)

Overall Status

Completed

CT.gov ID

NCT00376480

Collaborator

National Cancer Institute (NCI) (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Enrollment

Locations

Arm

155.5

Actual Duration (Months)

3.2

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methylprednisolone and antithymocyte globulin before transplant and peripheral blood cells that have been treated in the laboratory after transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated peripheral blood cell infusion after donor stem cell transplant in treating patients with hematologic cancers or other diseases.

Condition or Disease	Intervention/Treatment	Phase
Leukemia Myelodysplastic Syndromes	Biological: anti-thymocyte globulin Biological: peripheral blood lymphocyte therapy Drug: fludarabine phosphate Drug: methylprednisolone Drug: thiotepa Procedure: allogeneic hematopoietic stem cell transplantation Procedure: in vitro-treated peripheral blood stem cell transplantation Radiation: total-body irradiation	Phase 1

Detailed Description

OBJECTIVES:

Primary

Establish the feasibility of delayed infusion of ex vivo anergized donor peripheral blood mononuclear cells (PBMC) after CD34 (cluster designation 34)-selected megadose haploidentical hematopoietic stem cell transplantation (HSCT) in patients with hematopoietic cancers or other diseases.
Determine the feasibility of collecting parental allogeneic stimulator cells to induce anergy to the nonshared donor-recipient haplotype in these patients.
Determine the feasibility of collecting donor PBMC as a source of T cells for ex vivo anergization.
Determine the number of transplanted individuals who meet the criteria for proceeding to delayed infusion of ex vivo anergized donor PBMC.
Establish the safety of delayed infusion of ex vivo anergized donor PBMC by establishing the maximum number of donor T cells that can be infused without unacceptable graft-versus-host disease.

Secondary

Evaluate, in vitro, the induction and specificity of alloantigen hyporesponsiveness in donor PBMC after ex vivo anergization.
Assess, in vitro, the function of immune cells engrafted in these patients.
Assess, in vitro, whether alloantigen hyporesponsive donor T cells are present in these patients.
Develop, preliminarily, in vitro data on the extent of pathogen-specific immunity and its rate of recovery.
Describe the patterns of opportunistic infections in these patients.

OUTLINE: This is a multicenter, dose-escalation study of ex vivo anergized allogeneic peripheral blood mononuclear cells (PBMC). Patients who are treated on any dose level except dose level 1 are stratified according to age (under 17 [pediatric] vs 17 and over [adult]).

Myeloablative conditioning regimen: Patients undergo total-body irradiation twice daily on days -11 to -9. Patients also receive thiotepa IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 30 minutes on days -7 to -3, and anti-thymocyte globulin IV over 8 hours and methylprednisolone IV over 15-30 minutes on days -6 to -3.
Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo CD34-selected PBSCT on day 0.
Ex vivo anergized allogeneic PBMC infusion: If cells have engrafted and patients are free of active uncontrolled infection and graft-vs-host disease, patients undergo allogeneic or autologous PBMC infusion on day 35 or 42.

Cohorts of 3-8 patients receive escalating doses of ex vivo anergized allogeneic PBMCs until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 5 or 3 of 8 patients experience dose-limiting toxicity.

After completion of study, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Study Design

Study Type:

Interventional

Actual Enrollment :

19 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia

Actual Study Start Date :

Jun 1, 2005

Actual Primary Completion Date :

Jun 1, 2010

Actual Study Completion Date :

May 16, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: administration of adoptive donor lymphocyte infusion administration of donor lymphocytes made using costimulatory blockade ex vivo	Biological: anti-thymocyte globulin Biological: peripheral blood lymphocyte therapy Drug: fludarabine phosphate Drug: methylprednisolone Drug: thiotepa Procedure: allogeneic hematopoietic stem cell transplantation Procedure: in vitro-treated peripheral blood stem cell transplantation Radiation: total-body irradiation

Arm

Intervention/Treatment

Experimental: administration of adoptive donor lymphocyte infusion

administration of donor lymphocytes made using costimulatory blockade ex vivo

Biological: anti-thymocyte globulin

Biological: peripheral blood lymphocyte therapy

Drug: fludarabine phosphate

Drug: methylprednisolone

Drug: thiotepa

Procedure: allogeneic hematopoietic stem cell transplantation

Procedure: in vitro-treated peripheral blood stem cell transplantation

Radiation: total-body irradiation

Outcome Measures

Primary Outcome Measures

Feasibility of making and administering the adoptive T cell product [from conditioning through administration of anergized cells on day 35-42]
ability to collect sufficient cells, make anergized product with good viability, without contamination and infuse per study toxicity of the conditioning regimen, the likelihood of engraftment, and the subsequent percentage of individuals who would be eligible to receive aDLI were determined.
Safety of administering the adoptive T cell product on day 35-42 post haploidentical transplant [the period from aDLI infusion through D100]
rates of graft failure with CD34 selected product, adverse and severe adverse reactions attributable to infusion of anergized donor cells, including fever, hypotension, acute graft vs host disease, organ dysfunction
Alloreactivity engendered by administering the adoptive T cell product [from cell infusion through day 100]
occurrence and severity of acute GVHD

Secondary Outcome Measures

Efficacy in restoring adaptive immunity [from aDLI thorough 1 year]
incidence of viral infection and type of immune reconstitution by phenotype and function of T cells

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 50 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:
Acute lymphocytic leukemia
In ≥ second complete remission (CR), defined as < 5% blasts in bone marrow (BM) and no active extramedullary disease OR in first CR with any of the following high risk features:
History of induction failure
Philadelphia chromosome positive
t(4;11) by cytogenetic analysis
Any infant with MLL rearrangements on cytogenetic analysis
No relapse with isolated extramedullary disease after completion of prior treatment
Acute myeloid leukemia
Failed induction therapy after < 3 courses
In ≥ second CR, defined as < 5% blasts in BM and no active extramedullary disease OR in first CR with any of the following high-risk features:
History of induction failure = 5q- or monosomy 7 cytogenetic findings
Any of the following myelodysplastic syndromes:
Refractory anemia (RA) with excess blasts (RAEB) with a high International Prognostic Scoring System (IPSS) score or score of intermediate-1(INT-1) or intermediate-2 (INT-2)
RAEB in transformation with INT-1, INT-2, or high IPSS score
RA with INT-2 score
Patients must have a healthy, related donor who is at least genotypically HLA-A, B, C, and DR haploidentical to the patient
No suitably matched family donor defined by genotypic or phenotypic identity for ≥ 5/6 A, B, or DR loci
No immediately available genotypically matched (6/6) unrelated marrow donor
No immediately available umbilical cord blood donor with suitable cell dose after a search ≥ 2 months
Patients whose medical condition is at high risk of deteriorating or whose disease is at high risk of progression during a donor search are eligible
Has a parent with a haplotype that is disparate from that of the donor for the haplotype shared by the patient and parent, but not shared by the patient and donor OR patient is able to donate sufficient autologous cells by peripheral blood draw or unstimulated leukapheresis
No active CNS disease

PATIENT CHARACTERISTICS:

Room air O_2 saturation > 95% unless the lungs are involved with disease
No clinical evidence of pulmonary insufficiency unless the lungs are involved with disease
AST and ALT < 3 times upper limit of normal (ULN)*
Bilirubin < 2.0 mg/dL*
Creatinine < 2 times ULN OR creatinine clearance or glomerular filtration rate > 50% of the lower limit of normal
LVEF > 45% OR shortening fraction > 20%
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No active infection, defined as absence of an infectious diagnosis or (in patients who have had a recent positive infectious diagnosis) the resolution of fever, documentation of negative cultures or antigen testing, continuation or completion of a course of appropriate therapy, and presence of stable to resolving clinical symptoms
No evidence of HIV infection OR known HIV positivity NOTE: *Does not apply if liver is involved with disease

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior stem cell transplantation
No other concurrent immunosuppressive therapy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Childrens Hospital Los Angeles	Los Angeles	California	United States	90027-0700
2	University of Florida Health Science Center - Gainesville	Gainesville	Florida	United States	32610
3	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
4	Children's Hospital Boston	Boston	Massachusetts	United States	02115
5	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02115
6	M. D. Anderson Cancer Center at University of Texas	Houston	Texas	United States	77030-4009